BIO Comments on DoL Proposed Rule, “Improving Transparency into Pharmacy Benefit Manager Fee Disclosure”

Dear Colleagues,  I am just past the two-year mark as BIO’s President & CEO, which arrives as we find ourselves at a defining moment for the future of biotechnology. For fifty years, our industry has delivered one of the great…